Dr. Constantine K. Saadeh, M.D.
Rheumatology (Rheumatology Physician)
6842 Plum Creek Dr
Amarillo, TX 79124
Who else practices at this address →
Potter County includes primary care (100% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 44
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 962
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
TX license 102726 -
Allergy & Immunology (Internal Medicine) Physician
TX license 102726
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Bsa Hospital Amarillo, TX
- Northwest Texas Hospital Amarillo, TX
- Childress Regional Medical Center Childress, TX
- Ochiltree General Hospital Perryton, TX
- Union County General Hospital Clayton, NM
Medical groups
- Allergy Arts LLP (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 962
- Services billed
- 289,238
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Injection, tocilizumab, 1 mg | 38,320 | 15 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 25,050 | 54 |
| Injection, omalizumab, 5 mg | 16,185 | 26 |
| Injection, golimumab, 1 mg, for intravenous use | 12,552 | 20 |
| Professional service for preparation and provision of 1 or more antigens | 9,535 | 279 |
| Injection, denosumab, 1 mg | 9,360 | 100 |
| Test for allergy using allergenic extract | 9,080 | 95 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 8,100 | 12 |
| Injection, rituximab, 10 mg | 6,500 | 22 |
| Injection, infliximab, excludes biosimilar, 10 mg | 5,140 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Amarillo, TX | 673 |
| Hydroxychloroquine Sulfate Other prescribers in Amarillo, TX | 644 |
| Montelukast Sodium Other prescribers in Amarillo, TX | 417 |
| Methotrexate (methotrexate sodium) Other prescribers in Amarillo, TX | 365 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Amarillo, TX | 350 |
| Famotidine Other prescribers in Amarillo, TX | 341 |
| Gabapentin Other prescribers in Amarillo, TX | 255 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Amarillo, TX | 208 |
| Prednisone Other prescribers in Amarillo, TX | 195 |
| Leflunomide Other prescribers in Amarillo, TX | 164 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 72 payments worth $1,260 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $314 |
|---|---|
| Amgen Inc. | $283 |
| Blueprint Medicines Corporation | $102 |
| Sobi, Inc | $66.47 |
| Ionis Pharmaceuticals, Inc. | $62.31 |
| Grifols USA, LLC | $61.47 |
| UCB, Inc. | $52.79 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $50.80 |
| Food and Beverage | $1,260 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 6 companies. The companies reported $152,107 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity
Amgen Inc. - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity
Amgen Inc. - Hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)
Chugai Pharmaceutical Co., Ltd. - A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS)
Amgen Inc. - A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
E.r. Squibb & Sons, L.l.c. - A 52-week, randomised, double-blind, double-dummy, parallel group, mul
GlaxoSmithKline, LLC. - A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants
Amgen Inc. - Roche Cancer Screening Collection Study
Genentech, Inc. - A Study of Baricitinib in Participants With Rheumatoid Arthritis
Eli Lilly and Company · Completed · NCT04086745
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.